Although various CRISPR-Cas systems have been employed in previous mutant KRAS therapies20, this study presents, a precise and efficient CRISPR-Cas9 system that targets the oncogenic KRASG12C and KRASG12D alleles in NSCLC without impacting the wildtype KRAS. This study also represents a KRAS-editing strategy demonstrating therapeutic potential on preclinical NSCLC models. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.